Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-1: mevrometostat + enzalutamide versus physician's choice treatment in previously abiraterone-treated mCRPC
NL-OMON60864Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mevrometostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Pfizer. Primary endpoint: Radiographic progression-free survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
mevrometostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60864.